Methods and compositions for preventing or treating calciphylaxis
The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) calciphylaxis in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating calciphylaxis in a subject with one or more of the following: diabetes, chronic kidney disease, end stage renal failure, and COPD or a subject undergoing hemodialysis and/or receiving anticoagulant therapy and/or statin therapy.
1. A method of treating calciphylaxis in a human subject in need thereof, the method comprising administering to the human subject (a) menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7); and (b) a statin; whereupon the administration of the MK-7 and/or MKH2-7:
(i) increases a plasma level of Fetuin A relative to the plasma level of Fetuin A prior to administration; or
(ii) decreases a plasma level of Highly Sensitive C Reactive Protein (hs-CRP) relative to the plasma level of hs-CRP prior to administration.
2. The method of claim 1 , wherein the statin is selected from simvastatin, lovastatin, atorvastatin, pravastatin, pitavastatin, rosuvastatin, and fluvastatin.
3. The method of claim 1 , wherein from about 10 mg to about 50 mg of MK-7 and/or MKH2-7 is administered to the subject per day.
4. The method of claim 1 , wherein 10, 25, 50, 75 or 100 mg of MK-7 and/or MKH2-7 is administered to the subject per day.
5. The method of claim 1 , wherein the composition is administered to the subject for at least 2 weeks.
6. The method of claim 1 , wherein the composition is administered daily.
7. The method of claim 1 , wherein the composition is administered orally.
8. The method of claim 1 , wherein the subject is taking calcium-based phosphate binders and/or vitamin D analogs.
9. The method of claim 1 , wherein the MK-7 and/or MKH2-7 is administered in the same dosage form as the statin.
10. The method of claim 1 , wherein the MK-7 and/or MKH2-7 is administered in a separate dosage form from the statin.
11. The method of claim 1 , wherein the composition is administered to the subject for at least 6 weeks.
12. The method of claim 1 , wherein the subject is diabetic.
13. The method of claim 12 , wherein the subject is undergoing hemodialysis.
14. The method of claim 13 , wherein the composition is administered to the subject for a period that includes the duration of hemodialysis.
15. The method of claim 1 , wherein the composition is disposed within a tablet, caplet, or capsule.
16. The method of claim 1 , wherein the composition comprises MK-7 and/or MKH2-7 and a pharmaceutically acceptable excipient.
17. The method of claim 1 , wherein, prior to administration of the composition, the subject has a uremic oxidative blockade.
18. The method of claim 1 , whereupon administration of the MK-7 and/or MKH2-7 to the subject increases the subject's serum T50 value relative to the subject's serum T50 value prior to administration of the MK-7 and/or MKH2-7.
19. The method of claim 1 , wherein administration of the MK-7 and/or MKH2-7
(a) increases a ratio of a carboxylated to a non-carboxylated of a Vitamin K dependent protein or
(b) decreases an amount of a non-carboxylated Vitamin K dependent protein in plasma of the subject relative to the ratio or amount present prior to administration of the MK-7 and/or MKH2-7.
20. The method of claim 19 , wherein the Vitamin K-dependent protein is selected from Matrix Gla Protein, Growth Arrest Specific Gene 6 (Gas-6) protein, PIVKA-II protein, osteocalcin, activated Protein C, or activated Protein S.
21. The method of claim 1 , wherein administration of the MK-7 and/or MKH2-7 to the subject decreases a plasma level of D-Dimer relative to the plasma level of D-Dimer prior to administration of the MK-7 and/or MKH2-7.
22. The method of claim 1 , wherein at least about 10 mg of MK-7 and/or MKH2-7 is administered to the subject per day.
23. The method of claim 1 , wherein the MK-7 and/or MKH2-7 is substantially pure.
24. The method of claim 1 , whereupon the administration of the MK-7 and/or MKH2-7 increases a plasma level of Fetuin A relative to the plasma level of Fetuin A prior to administration.
25. The method of claim 1 , wherein at least about 10 mg of substantially pure MK-7 and/or MKH2-7 is administered to the subject per day, whereupon the administration of the MK-7 and/or MKH2-7 increases a plasma level of Fetuin A relative to the plasma level of Fetuin A prior to administration.